25 July 2025 French diabetes and obesity specialist Adocia was trading 45% higher late Friday following its partner Tonghua Dongbao’s release of positive topline results from the Phase III trial of BioChaperone Lispro (THDB0206 injection), a novel ultra-rapid insulin formulation.
As many as 19 of the top 20 publicly-traded global biopharma companies reported revenue growth in 2024, with an overall 7.9% year-on-year (YoY) increase in aggregate revenue to $880.4 billion, reveals GlobalData. 29 July 2025
Shares in CervoMed were up 6% Monday lunchtime after the US company announced positive 32-week data from the extension phase of the Phase IIb RewinD-LB trial showing that oral neflamapimod continues to slow disease progression and demonstrate an effect on a plasma marker of neurodegeneration in dementia with Lewy bodies (DLB). 28 July 2025
US clinical-stage oncology focused biotech Celcuity saw its shares skyrocket 180% to $38.59 in early trading as it announced positive trial data for its lead candidate gedatolisib. 28 July 2025
Hong Kong-based biotech Neuco United and Shanghai Fosun Pharmaceutica have signed an exclusive licensing agreement for the manufacturing and commercialization of AR1001 in Greater China, encompassing the Chinese mainland, Hong Kong and Macau. 28 July 2025
Jiangsu Hengrui Pharmaceuticals shares rallied to their highest level in four years – leaping 10% to 62.04 renminbi - after UK pharma major GSK announced a deal with the Chinese company. 28 July 2025
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved US biotech Biogen’s Qalsody (tofersen) to treat adults with amyotrophic lateral sclerosis (ALS) caused by mutations in the SOD1 (an enzyme called superoxide dismutase 1) gene – a rare, inherited form of motor neurone disease (MND). 28 July 2025
World Hepatitis Day, marked each year on July 28, is shining a light on what GlobalData calls an “urgent need” for a renewed push to tackle viral hepatitis as mortality rises worldwide. The disease remains among the deadliest infectious threats, affecting more than 300 million people globally. 28 July 2025
A new European project, called Greg, has been launched to tackle long-standing challenges around the use of real-world data and evidence in medicines, medical devices, and drug-device combinations. 28 July 2025
Boehringer Ingelheim and Re-Vana Therapeutics, a USA and UK based developer of ocular therapeutics and ocular drug delivery technologies, today announced a strategic collaboration and license agreement that aims to develop first-in-class extended-release therapies for eye diseases. 28 July 2025
China has recently approved the first locally developed obesity drug Xinermei (mazdutide), marking a critical milestone in the country’s obesity treatment landscape. 28 July 2025
For millions in low- and middle-income countries (LMICs), lifesaving medicines remain out of reach. While the pharmaceutical industry continues to deliver record-breaking innovation, access to those breakthroughs is often determined by cruel lotteries of geography and income. 28 July 2025
The information portal on the entry of new medicines and indications shows the number of new medicines and indications (expanding the possibilities of treating various types of diseases with given medicines) included in the standard system of reimbursement from public health insurance, the Slovak pharma trade group AIFP noted in a website posting. 28 July 2025
The US Food and Drug Administration (FDA) has notified Bayer that it has extended the review period for the New Drug Application (NDA) for elinzanetant, the first neurokinin 1 and neurokinin 3 receptor antagonist for the treatment of moderate to severe vasomotor symptoms (VMS; also known as hot flashes) due to menopause. 26 July 2025
US pharma major Bristol Myers Squibb revealed it has appointed Dr Cristian Massacesi as executive vice president, chief medical officer and head of development, effective August 1, 2025. 26 July 2025
French diabetes and obesity specialist Adocia was trading 45% higher late Friday following its partner Tonghua Dongbao’s release of positive topline results from the Phase III trial of BioChaperone Lispro (THDB0206 injection), a novel ultra-rapid insulin formulation. 25 July 2025
The European Medicines’ (EMA) human medicines committee (CHMP) has recommended seven novel medicines for approval at its July 2025 meeting. 25 July 2025
Semaglutide, a GLP-1R agonist developed by Denmark’s Novo Nordisk as Ozempic, initially for type 2 diabetes, and marketed under the trade name Wegovy for obesity, is emerging as a promising candidate for neurological conditions. 25 July 2025
The Trump administration has asked the US Supreme Court to allow the National Institutes of Health (NIH) to resume canceling hundreds of research grants supporting work on health equity, racial disparities, and other diversity-related public health initiatives. 25 July 2025
In Europe, revised rules for the Clinical Trials Information System (CTIS) are now applicable, offering faster access to clinical trial information. 18 June 2024
The Russian pharmaceutical market is undergoing a large-scale transformation, as the share of foreign drugs is steadily declining due to acceleration of processes of import substitution, reports The Pharma Letter’s local correspondent. 18 June 2024
Shares of US drug developer Aerovate Therapeutics plummeted 93% yesterday and were down a further 6.7% at $1.54 pre-market, after it revealed it would scrap a late-stage development of its lead investigational candidate. 18 June 2024
The US unit of Japan’s Mitsubishi Tanabe Pharma has announced results from two studies of its already marketed Radicava (edaravone) for amyotrophic lateral sclerosis (ALS) at the European Network to Cure Amyotrophic Lateral Sclerosis (ENCALS) 2024 meeting. 18 June 2024
Johnson & Johnson continues to be the world's most valuable and strongest pharmaceutical brand, according to a new report by Brand Finance. 18 June 2024
Takeda, Japan’s largest drugmaker, today announced mixed top-line data from its SKYLINE and SKYWAY Phase III trials outcomes for its drug soticlestat. 17 June 2024
Japanese drugmaker Mitsubishi Tanabe Pharma (MTPC) has entered into an agreement with Paris, France-based Ethypharm for the transfer of the business of the selective antithrombin agent, argatroban monohydrate in Europe. 17 June 2024
"There is a need for good conditions for entrepreneurs in Denmark. It is an important piece if we hope to maintain and expand our global position, not least within life science and biotech," says Ida Sofie Jensen, chief executive of the Danish Pharmaceutical Industry Association, Lif. 17 June 2024
A recent survey from IDC highlights that 49% of the pharmaceutical industry believes they have achieved success in implementing artificial intelligence (AI) across the entire pharmacovigilance (PV) value chain. However, over the next two years, the industry expects this number to only marginally shift to just 51%. 17 June 2024
The US Food and Drug Administration (FDA) yesterday granted accelerated approval to Augtyro (repotrectinib), from Bristol Myers Squibb), for a new indication. 14 June 2024
Bladder cancer specialist UroGen Pharma saw its shares close up nearly 38% at $17.50 yesterday, after it shared positive trial results on its lead pipeline candidate UGN-102, an innovative formulation of mitomycin. 14 June 2024
As the UK heads for a general election next month, the Association of the British Pharmaceutical Industry (ABPI) today assessed the Labour Party manifesto, having yesterday appraised the UK Conservative pledges. 13 June 2024
Alzheon, a clinical-stage biopharma company, has secured $100 million in a series E funding round led by Alerce Medical Technology Partners. 13 June 2024
Johnson & Johnson says it has “grave concern” for the availability of future innovative mental health treatments in England, following a decision by National Institute for Health and Care Excellence (NICE) to not re-appraise Spravato (esketamine nasal spray) for treatment-resistant depression in England 13 June 2024
AstraZeneca’s Farxiga (dapagliflozin) has received approval from the US Food and Drug Administration to improve glycemic control in children with type-2 diabetes (T2D). 13 June 2024
Aardvark Therapeutics might not have scored the biggest venture haul in May, but its $85 million Series C round will further strengthen rumors that the California-based company is gearing up for an IPO this summer, which could come as soon as late July. 13 June 2024
The US Centers for Medicare & Medicaid Services’ (CMS) Office of the Actuary has released projections of National Health Expenditures (NHE) and health insurance enrollment for the years 2023-2032. 13 June 2024
Flagship Pioneering and its founded company ProFound Therapeutics today announced a collaboration to conduct foundational research to identify potential next-generation first-in-class therapies for the treatment of obesity. 12 June 2024